Welcome to NeurologyLive®‘s Friday 5! Each week, the employees compiles 5 highlights of NeurologyLive®‘s widespread protection in neurology, starting from newsworthy research findings and FDA motion to professional interviews and peer-to-peer panel discussions.
1: Overviewing Updating Amyloid and Tau PET Standards to Improve Alzheimer Diagnostic Precision: Phillip Kuo, MD, PhD, FACR
The professor within the division of diagnostic radiology at Metropolis of Hope mentioned a newly up to date revealed guideline for amyloid and tau PET imaging geared in the direction of bettering Alzheimer analysis. [WATCH TIME: 5 minutes]
2: Advancing Understanding of the Preclinical Part of A number of Sclerosis: Christina J. Azevedo, MD
On the 2024 ECTRIMS Congress, the affiliate professor of scientific neurology at Keck College of Drugs of USC talked about latest analysis that highlights the preclinical section of a number of sclerosis. [WATCH TIME: 9 minutes]
3: Affect of COVID-19 Vaccination on Neurologic Manifestations of Lengthy COVID: Igor Koralnik, MD
The chief of neuroinfectious ailments and world neurology at Northwestern Drugs mentioned a not too long ago revealed research that highlighted Lengthy COVID’s vital scientific and societal affect. [WATCH TIME: 5 minutes]
4:NeuroVoices: Nigel Bunnett, PhD, BSc, on Figuring out a Novel Therapeutic Goal for Persistent Ache
The professor and chair of the Division of Molecular Pathobiology at NYU School of Dentistry mentioned groundbreaking analysis on power ache, specializing in the invention of latest mechanisms involving nerve development issue and its receptors.
5: Medical Program and Subsequent Steps for Zorevunersen as Potential Illness-Modifying Therapy for Dravet: Barry Ticho, MD, PhD
The chief medical officer at Stoke Therapeutics mentioned latest developments for zorevunersen, together with the importance of breakthrough remedy designation and its plan for a section 3 trial. [WATCH TIME: 5 minutes]
